1. Home
  2. BGMS vs DRMA Comparison

BGMS vs DRMA Comparison

Compare BGMS & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bio Green Med Solution Inc.

BGMS

Bio Green Med Solution Inc.

N/A

Current Price

$1.03

Market Cap

5.0M

Sector

N/A

ML Signal

N/A

Logo Dermata Therapeutics Inc.

DRMA

Dermata Therapeutics Inc.

HOLD

Current Price

$1.33

Market Cap

5.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BGMS
DRMA
Founded
1996
2014
Country
Malaysia
United States
Employees
N/A
9
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.0M
5.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BGMS
DRMA
Price
$1.03
$1.33
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
81.4K
1.9M
Earning Date
05-14-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$137.21
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.73
$0.59
52 Week High
$6.70
$7.33

Technical Indicators

Market Signals
Indicator
BGMS
DRMA
Relative Strength Index (RSI) 49.85 49.26
Support Level $0.74 $1.14
Resistance Level $1.13 $1.84
Average True Range (ATR) 0.10 0.16
MACD 0.01 0.01
Stochastic Oscillator 49.84 31.08

Price Performance

Historical Comparison
BGMS
DRMA

About BGMS Bio Green Med Solution Inc.

Bio Green Med Solution Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.

About DRMA Dermata Therapeutics Inc.

Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology for patients suffering with acne. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin.

Share on Social Networks: